Building a Global Pharmaceutical Platform
Our Commercial Portfolio
Specialized Brand Divisions
Skinvil
Advanced Care for Timeless Skin. A premium skincare brand offering scientifically backed dermatological solutions and advanced cosmetic therapeutics.
💊 Good Choice
Single Pack Supplements. Essential daily nutraceutical products and vitamins formulated to support global wellness and nutritional health.
🦷 Oravil
Oral Health Care Redefined. Next-generation oral care formulations including antiseptic rinses and specialized dental health preparations.
The Growing Global Pharmaceutical Opportunity
Five markets. Five entry points. One integrated group.
Projected export market by 2030 – India is the pharmacy of the world
GMP-certified manufacturing base in Uttarakhand with 1,000+ approved molecules and active export operations across 13 therapeutic categories
Annual US generics market – the world's single largest opportunity for Indian pharma
Operational US subsidiary with signed manufacturing supply agreement with Westminster Pharmaceuticals Inc. and marketing deal with Activpower Inc., Virginia
Global oncology market growth – the fastest-growing therapeutic segment worldwide
Dedicated oncology division under Chemgenix – targeting cancer therapeutics and biosimilars, an unlisted high-growth asset within the listed group
Population across CARICOM nations – underserved by quality generic manufacturers
Vilin Bio Med Jamaica – first-mover advantage as Caribbean and Latin American market entry vehicle in a largely untapped region
Projected global biologics market by 2030 – peptides and biosimilars driving the next wave
Dedicated biologics pipeline via Vilin Biotherapeutics R&D – targeting peptides, biosimilars, and next-generation oncology molecules
Financial Highlights
Performance markers reported in INR Crores
Accelerated top-line revenue driven by expanding international distribution channels and higher capacity utilization at our manufacturing base.
Group net profits expanded rapidly, highlighting enhanced cost efficiencies and a stronger product mix focusing on niche formulations.
Strong consolidated performance trajectory showing rapid market capture across our domestic and global formulations channels.
Robust equity reserves supporting continuous R&D pipelines development, formulation testing, and international regulatory approvals.
Robust standalone business turnover driving capital-efficient operations and setting the base for high-growth global generic markets expansion.
Healthy cash operating margin before interest and tax adjustments, reflecting resilient cost management inside our manufacturing facilities.
Standalone net profit surged by 37.50%, showcasing superior business efficiency, overhead reductions, and strong margins optimization.
Basic earning capacity per common share rose to ₹0.16, strengthening the underlying book value and equity valuation on the exchange.
Our Connected Global Network
Five distinct corporate entities under one cohesive pharmaceutical framework spanning India, the US, and emerging Latin American/Caribbean markets.
Vilin Bio Med Limited
Parent Company · NSE ListedOur state-of-the-art formulations manufacturing plant in Roorkee houses robust R&D, processing 1,000+ molecules across 13 therapeutic categories.
Vilin Bio Med Inc.
United States SubsidiaryDirects North American supply chains. Partners with Westminster Pharmaceuticals Inc. and Activpower Inc. to distribute formulations across the US market.
Vilin Oncology
Chemgenix DivisionSpecialized division focused on cancer therapeutics, biosimilars, and targeted oncology molecules. Operates as a high-growth asset within the group.
Vilin Bio Med Jamaica
Caribbean EntityOur market entry and distribution vehicle for the CARICOM trade region, establishing local manufacturing pipelines in underserved Latin American markets.
Vilin Biotherapeutics
R&D & Innovation CentreFocused on advanced biologics, biosimilars, novel drug delivery systems (NDDS), clinical research, and next-generation biopharma innovation.
Group Entities
Our Connected Global Network
Four distinct entities. One cohesive pharma framework spanning India, the US, and emerging Latin American/Caribbean markets.
Vilin Bio Med Limited
Parent Company · NSE Listed
📍 Hyderabad & Roorkee, India
Formulations manufacturing base, 1,000+ molecules, 13 therapeutic categories, state-of-the-art facility in Uttarakhand.
Vilin Bio Med Inc.
United States Subsidiary
📍 Edison, NJ & Sheridan, WY
North American market supply node. Product supply agreement signed with Westminster Pharmaceuticals; marketing contract with Activpower Inc., Virginia.
Vilin Oncology
Chemgenix Division
📍 Hyderabad, India
Dedicated oncology brand therapeutics. Target molecule pipeline focuses on complex cancer treatments, peptides, biosimilars, and active pharmaceutical inputs.
Vilin Bio Med Jamaica
Caribbean Entity
📍 Kingston, Jamaica
CARICOM regional market entry vehicle. Establishing first-mover advantages to manufacture and distribute generics in underserved Caribbean & Latin America.
Press Room
Market Disclosures & Corporate Updates
Regulatory announcements, licensing updates, and business distribution agreements officially filed.
Manufacturing Agreement with Westminster Pharmaceuticals Inc., USA
Vilin Bio Med Limited has entered into a Product Manufacturing and Supply Agreement with Westminster Pharmaceuticals Inc., USA to support long-term supply of select pharmaceutical formulations for the U.S. market — representing a major milestone in the Group’s North American exports execution.
Calendar Year: 2025
Supply & Distribution Partnership with Activpower Inc., USA
Vilin Bio Med Inc. has expanded its U.S. commercial presence through a strategic distribution collaboration with Activpower Inc., strengthening market access and enhancing supply chain execution for regulated pharmaceutical products across North America.
Year: 2025, Market Expansion: United States
Semaglutide Manufacturing Licence Granted — No. UA/Test/2026
Vilin Bio Med Roorkee (Unit II) has been licensed to manufacture Semaglutide Tablets in 3.0mg, 7.0mg, and 14.0mg strengths by the State Licensing Authority. This approval strengthens the company’s capabilities in advanced metabolic and anti-diabetic therapeutics, while positioning the Group for future participation in high-growth global GLP-1 pharmaceutical markets.
Date: May 2026
R&D Partnership with Optin Pharma Formalised
Partnership focused on next-generation formulation technologies, enhancing complex APIs development capability. The collaboration is expected to accelerate innovation in modified-release systems, bioavailability enhancement, and scalable specialty formulations, while strengthening the Group’s long-term research pipeline.
Date: 2026
Leadership
Management
Steering Vilin Bio Med with global compliance and industry integrity.
Managing Director
Dr.Madhu Sudhan Reddy
Promoter & MD
Founding promoter with over two decades of experience in pharmaceutical plant administration, formulations research, and corporate expansion. At Vilin Bio Med, we don’t just adapt to change, we lead it. Together, we will set new benchmarks in global healthcare and create a lasting impact on millions of lives. The future starts now, and I look forward to working with you all to make a real difference.
Investor Relations
Corresponding Details
Vilin Bio Med is committed to absolute transparency. Find all required SEBI filings, quarterly results, shareholding dynamics, and compliance notices in our centralized investor center.
IR Contact Channels
- Business Dev: bd@vilinbio.com
- India Tel: +91 91777 37111, 9908684438
- USA Tel: +1 571 5714 720
Financial Results
Quarterly, half-yearly, and annual balance sheets, P&L, and cash flow reports.
Annual Reports
Complete annual fiscal audits, governance disclosures, and directors reports.
Shareholding Pattern
Quarterly updates representing promoter, public, and institutional equity distributions.
AGM & Board Meetings
Notices, resolutions, voter guidance, and meeting transcript records.
Corporate Governance
Composition of committees, charters, board evaluations, and code of conduct policies.
Investor Grievance
SEBI SCORES system portal link for resolving shareholder concerns.